Is MCRB or TVRD more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Tvardi Therapeutics N/A -64.17% -43.90%

Does the media prefer MCRB or TVRD?

In the previous week, Tvardi Therapeutics had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 7 mentions for Seres Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.61 beat Seres Therapeutics' score of 0.07 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is TVRD or ACRV more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Acrivon Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Acrivon Therapeutics N/A -64.43% -57.08%

Does the media refer more to HYFT or TVRD?

In the previous week, Tvardi Therapeutics had 5 more articles in the media than MindWalk. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 5 mentions for MindWalk. Tvardi Therapeutics' average media sentiment score of 0.61 beat MindWalk's score of 0.52 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is TVRD or CING more profitable?

Tvardi Therapeutics' return on equity of -64.17% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -64.17% -43.90% Cingulate N/A -365.15% -158.55%

Is PLRX or TVRD more profitable?

Pliant Therapeutics' return on equity of -58.11% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Pliant Therapeutics N/A -58.11% -44.37% Tvardi Therapeutics N/A -64.17% -43.90%

Does the media prefer PLRX or TVRD?

In the previous week, Tvardi Therapeutics had 7 more articles in the media than Pliant Therapeutics. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.87 beat Tvardi Therapeutics' score of 0.61 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tvardi Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Tvardi Therapeutics (TVRD) Competitors

$3.10 -0.21 (-6.34%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$3.16 +0.05 (+1.77%)

As of 07/14/2026 07:50 PM Eastern

Compare

TVRD vs. MCRB, ACRV, HYFT, CING, and PLRX

Should you buy Tvardi Therapeutics stock or one of its competitors? MarketBeat compares Tvardi Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tvardi Therapeutics include Seres Therapeutics (MCRB), Acrivon Therapeutics (ACRV), MindWalk (HYFT), Cingulate (CING), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry.

How does Tvardi Therapeutics compare to Seres Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 218.35%. Tvardi Therapeutics has a consensus price target of $19.67, indicating a potential upside of 534.41%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Tvardi Therapeutics' return on equity of -64.17% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Tvardi Therapeutics had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 7 mentions for Seres Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.61 beat Seres Therapeutics' score of 0.07 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Seres Therapeutics has higher earnings, but lower revenue than Tvardi Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$1.15M	45.09	$5.70M	-$5.17	N/A
Tvardi Therapeutics	$7.14M	4.07	-$18.21M	-$3.10	N/A

Summary

Tvardi Therapeutics beats Seres Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Acrivon Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and dividends.

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tvardi Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market.

Tvardi Therapeutics' return on equity of -64.17% beat Acrivon Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

In the previous week, Tvardi Therapeutics had 9 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 1 mentions for Acrivon Therapeutics. Acrivon Therapeutics' average media sentiment score of 1.87 beat Tvardi Therapeutics' score of 0.61 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Tvardi Therapeutics	Positive
Acrivon Therapeutics	Very Positive

Tvardi Therapeutics currently has a consensus price target of $19.67, suggesting a potential upside of 534.41%. Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 447.73%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tvardi Therapeutics is more favorable than Acrivon Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Tvardi Therapeutics has higher revenue and earnings than Acrivon Therapeutics. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	4.07	-$18.21M	-$3.10	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Summary

Tvardi Therapeutics beats Acrivon Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

MindWalk has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

In the previous week, Tvardi Therapeutics had 5 more articles in the media than MindWalk. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 5 mentions for MindWalk. Tvardi Therapeutics' average media sentiment score of 0.61 beat MindWalk's score of 0.52 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

6.7% of MindWalk shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tvardi Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Tvardi Therapeutics' return on equity of -64.17% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Tvardi Therapeutics has lower revenue, but higher earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	3.88	-$21.69M	-$0.20	N/A
Tvardi Therapeutics	$7.14M	4.07	-$18.21M	-$3.10	N/A

MindWalk currently has a consensus target price of $5.00, indicating a potential upside of 237.84%. Tvardi Therapeutics has a consensus target price of $19.67, indicating a potential upside of 534.41%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Tvardi Therapeutics beats MindWalk on 12 of the 16 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Cingulate?

Tvardi Therapeutics (NASDAQ:TVRD) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Tvardi Therapeutics presently has a consensus price target of $19.67, indicating a potential upside of 534.41%. Cingulate has a consensus price target of $27.33, indicating a potential upside of 480.33%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tvardi Therapeutics is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Tvardi Therapeutics had 9 more articles in the media than Cingulate. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 1 mentions for Cingulate. Cingulate's average media sentiment score of 0.93 beat Tvardi Therapeutics' score of 0.61 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Tvardi Therapeutics	Positive
Cingulate	Positive

Tvardi Therapeutics has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	4.07	-$18.21M	-$3.10	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

Tvardi Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.91, indicating that its share price is 191% less volatile than the broader market.

Tvardi Therapeutics' return on equity of -64.17% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-64.17%	-43.90%
Cingulate	N/A	-365.15%	-158.55%

Summary

Tvardi Therapeutics beats Cingulate on 14 of the 15 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Pliant Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

Pliant Therapeutics' return on equity of -58.11% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-58.11%	-44.37%
Tvardi Therapeutics	N/A	-64.17%	-43.90%

In the previous week, Tvardi Therapeutics had 7 more articles in the media than Pliant Therapeutics. MarketBeat recorded 10 mentions for Tvardi Therapeutics and 3 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.87 beat Tvardi Therapeutics' score of 0.61 indicating that Pliant Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pliant Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tvardi Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tvardi Therapeutics has higher revenue and earnings than Pliant Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58M	42.72	-$149.34M	-$1.84	N/A
Tvardi Therapeutics	$7.14M	4.07	-$18.21M	-$3.10	N/A

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 175.23%. Tvardi Therapeutics has a consensus target price of $19.67, suggesting a potential upside of 534.41%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tvardi Therapeutics is more favorable than Pliant Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

Pliant Therapeutics and Tvardi Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$31.05M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-1.00	20.98	27.01	24.38
Price / Sales	4.07	311.11	522.34	92.57
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	1.39	8.54	10.80	6.33
Net Income	-$18.21M	$23.83M	$3.59B	$331.02M
7 Day Performance	-38.00%	-2.77%	-1.49%	-0.33%
1 Month Performance	16.10%	5.85%	2.79%	-1.29%
1 Year Performance	-88.13%	52.15%	28.56%	21.30%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	2.8124 of 5 stars	$3.10 -6.3%	$19.67 +534.4%	-89.6%	$31.05M	$7.14M	N/A	80
MCRB Seres Therapeutics	3.2745 of 5 stars	$7.74 flat	$17.00 +119.6%	-64.0%	$74.95M	$790K	N/A	330
ACRV Acrivon Therapeutics	2.4138 of 5 stars	$1.72 flat	$11.67 +578.3%	+60.2%	$73.62M	N/A	N/A	58
HYFT MindWalk	3.1436 of 5 stars	$1.57 flat	$5.00 +218.5%	N/A	$72.47M	$17.59M	N/A	80	Gap Up
CING Cingulate	3.1579 of 5 stars	$5.38 flat	$27.33 +408.1%	-0.4%	$72.46M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. MCRB, ACRV, HYFT, CING, and PLRX

How does Tvardi Therapeutics compare to Seres Therapeutics?

Summary

How does Tvardi Therapeutics compare to Acrivon Therapeutics?

Summary

How does Tvardi Therapeutics compare to MindWalk?

Summary

How does Tvardi Therapeutics compare to Cingulate?

Summary

How does Tvardi Therapeutics compare to Pliant Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. MCRB, ACRV, HYFT, CING, and PLRX

How does Tvardi Therapeutics compare to Seres Therapeutics?

Do analysts prefer MCRB or TVRD?

Is MCRB or TVRD more profitable?

Do institutionals & insiders hold more shares of MCRB or TVRD?

Does the media prefer MCRB or TVRD?

Which has more risk and volatility, MCRB or TVRD?

Which has higher valuation & earnings, MCRB or TVRD?

Summary

How does Tvardi Therapeutics compare to Acrivon Therapeutics?

Do insiders & institutionals hold more shares of TVRD or ACRV?

Which has more risk and volatility, TVRD or ACRV?

Is TVRD or ACRV more profitable?

Does the media prefer TVRD or ACRV?

Do analysts rate TVRD or ACRV?

Which has preferable earnings & valuation, TVRD or ACRV?

Summary

How does Tvardi Therapeutics compare to MindWalk?

Which has more risk and volatility, HYFT or TVRD?

Does the media refer more to HYFT or TVRD?

Do institutionals and insiders believe in HYFT or TVRD?

Is HYFT or TVRD more profitable?

Which has stronger earnings & valuation, HYFT or TVRD?

Do analysts recommend HYFT or TVRD?

Summary

How does Tvardi Therapeutics compare to Cingulate?

Do institutionals and insiders believe in TVRD or CING?

Do analysts prefer TVRD or CING?

Does the media prefer TVRD or CING?

Which has preferable valuation & earnings, TVRD or CING?

Which has more risk & volatility, TVRD or CING?

Is TVRD or CING more profitable?

Summary

How does Tvardi Therapeutics compare to Pliant Therapeutics?

Which has more volatility & risk, PLRX or TVRD?

Is PLRX or TVRD more profitable?

Does the media prefer PLRX or TVRD?

Do insiders & institutionals hold more shares of PLRX or TVRD?

Which has stronger valuation & earnings, PLRX or TVRD?

Do analysts rate PLRX or TVRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools